SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

INTRODUCTION: HIV remains a global health challenge with a reported 39 million people living with HIV (PLHIV) in 2022. Sub-Saharan Africa, Asia and the Pacific are home to 82% of...

Background HIV/AIDS may cause malnutrition, both directly and indirectly, through common infections. This systematic review and meta-analysis aim to evaluate the effects of nutritional interventions on nutritional status, immunological status,...

Background Achieving and maintaining viral suppression and optimal adherence to antiretroviral therapy are crucial for improving health outcomes in general population of people living with HIV. This study aimed to...

Pregnancy introduces significant physiological changes that alter the pharmacokinetics (PK) of antiretroviral therapy (ART), impacting its safety and efficacy in HIV-positive women. Optimizing ART during pregnancy is critical to maintaining...

Objective Adolescents and young adults (AYA) with HIV are a population at high risk of experiencing mental issues and sleep disorder. We aim to summarise the global prevalence and risks...

BACKGROUND/OBJECTIVES: Access to antiretroviral (ARV) drugs remains a critical challenge in achieving the WHO/UNAIDS 95-95-95 targets, with medication costs representing a substantial barrier. This systematic review evaluates the effect of...

Background Women living with HIV (WLHIV), mostly in East Africa, are six times more likely to develop cervical cancer and are a priority population for secondary prevention. Numerous primary studies...

INTRODUCTION: The “Universal Test and Treat” (UTT) era for antiretroviral therapy (ART) increased HIV service delivery to children and adolescents aged 0-19 with HIV. The goal is to reach ƒ%95%...

Aim: Bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) is a single-tablet regimen approved for the treatment of HIV-1 in treatment-naive (TN) and virologically suppressed people with HIV-1 (PWH). While the efficacy of...

Objective: We conducted a systematic review evaluating the extant literature examining the impacts of cannabis use on HIV-related outcomes among Black sexual minoritized men (BSMM). Design: A systematic review. Methods: We conducted a...

Purpose: HIV-1 disrupts the metabolic profile of people living with HIV (PLWH), including the Tryptophan-Kynurenine (Trp-Kyn) pathway, linked to disease outcomes and comorbidities. Despite numerous studies, consensus on key dysregulated metabolites...

Purpose: This study evaluated the efficacy and safety of cabotegravir/rilpivirine long-acting formulation compared to oral standard of care at 48 and 52 weeks. Method: We conducted an electronic search (2005-2024) across databases...